The World Health Organization recommended against using Gilead Sciences Inc.’s remdesivir to treat hospitalized COVID-19 patients less than a month after U.S. regulators granted the drug a speedy approval.
“There is currently no evidence that it improves survival or the need for ventilation,” a panel of WHO-convened experts developing COVID-19 treatment guidelines said in The BMJ medical journal.
